Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.71 |
| ▸ | DRD3 | P35462 | 3/20 | 0.71 |
| ▸ | HTR1A | P08908 | 5/20 | 0.69 |
| ▸ | HTR7 | P34969 | 6/20 | 0.63 |
| ▸ | DRD5 | P21918 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080790 | 1.00 | DRD2 (0.71) | DRD2DRD3HTR1AHTR7DRD5 | |
| SCHEMBL6954563 | 0.96 | HTR1A (0.71) | DRD2DRD3HTR1AHTR7DRD5 | |
| SCHEMBL6246397 | 0.92 | DRD2 (0.69) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL27678005 | 0.87 | DRD2 (0.54) | DRD2DRD3HTR1AHTR7DRD5 | |
| SCHEMBL6526368 | 0.87 | DRD2 (0.85) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL7054947 | 0.85 | HTR7 (0.53) | DRD2DRD3HTR1AHTR7DRD5 | |
| SCHEMBL7057457 | 0.84 | DRD3 (0.54) | DRD2DRD3HTR1ASLC6A4 | |
| SCHEMBL30206503 | 0.83 | DRD2 (0.78) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL1255253 | 0.83 | DRD2 (0.78) | DRD2DRD3HTR1AHTR7MEN1 | |
| SCHEMBL10414460 | 0.83 | DRD2 (1.00) | DRD2DRD3HTR1AHTR7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329282-B | Phenylpiperazine derivative and preparation method and application thereof | 新乡医学院 | 2022-01-07 | — | — | CN | claimed |
| CN-117263843-A | Dopamine D 2 Receptor-like dual ligand compounds and uses thereof | 常州大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-109419802-B | Compounds having dopamine D3 receptor modulating activity and uses thereof | 中国人民解放军军事医学科学院毒物药物研究所（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-108329282-B | Phenylpiperazine derivative and preparation method and application thereof | 新乡医学院 | 2022-01-07 | — | — | CN | disclosed |
| CN-109419802-A | Active compound and application thereof is adjusted with dopamine D 3 receptor | 中国人民解放军军事医学科学院毒物药物研究所 | 2019-03-05 | — | — | CN | disclosed |
| US-7875617-B2 | N-[4-(2-methoxyphenyl)piperazin-1-yl)butyl]-3,4-dihydro-6-fluoro-2-naphthamide for treating neuropsychological disorder selected from Parkinson's disease, schizophrenia and depression; partial agonists or antagonists of the dopamine D3 receptor | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20090124630-A1 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-1841752-B1 | 3,4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2008-12-10 | — | — | EP | disclosed |
| CN-101137645-A | Arylpiperazine derivatives for the treatment of neuropsychiatric disorders | UNIV SIENA (IT) | 2008-03-05 | — | — | CN | disclosed |
| EP-1841752-A1 | 3,4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077487-A1 | 3,4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-07-27 | — | — | WO | disclosed |
| EP-1683790-A1 | 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-07-26 | — | — | EP | disclosed |
| EP-0779284-B1 | Novel 2-naphthamide derivatives and their use in therapy as D3 receptor agonists | INST NAT SANTE RECH MED (FR) | 2002-07-10 | — | — | EP | disclosed |
| US-5985895-A | 2-naphthamide derivatives and their therapeutic applications | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM (FR) | 1999-11-16 | — | — | US | disclosed |
| US-5872119-A | 2-Naphthamide derivatives and their therapeutic applications | Institut National De La Sante et De La Recherche Medicale--INSERM (FR) | 1999-02-16 | — | — | US | disclosed |
| EP-0779284-A1 | Novel 2-naphthamide derivatives and their use in therapy as D3 receptor agonists | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124630-A1 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS | DRD3, SLC6A3, DRD2 | DRD2 3/4885DRD3 1/4885HTR1A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.